Aim: This study aimed to evaluate the association between N-acetyltransferase 2 (NAT2) gene polymorphisms and the risk of antituberculosis drug-induced liver injury (ATLI). Materials & methods: A meta-analysis was performed including 27 studies with 1289 cases and 5462 controls. Odds ratio with 95% CI was used to evaluate the strength of association. Results: Our meta-analysis found that NAT2 slow acetylators were associated with increased risk of ATLI compared with fast and intermediate acetylators when standard dose of isoniazid was administrated (odds ratio: 3.08; 95% CI: 2.29-4.15). Conclusion: Individuals with NAT2 slow acetylators may have increased risk of ATLI when standard dose of isoniazid was used. Detection of NAT2 genotype may benefit to the prevention of ATLI.
第一作者单位：[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Dept Respirat & Crit Care Med, Wuhan 430030, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Shi Jing,Xie Min,Wang Jianmiao,et al.Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis[J].PHARMACOGENOMICS.2015,16(18):2083-2097.doi:10.2217/pgs.15.144.
APA：
Shi, Jing,Xie, Min,Wang, Jianmiao,Xu, Yongjian&Liu, Xiansheng.(2015).Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.PHARMACOGENOMICS,16,(18)
MLA：
Shi, Jing,et al."Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis".PHARMACOGENOMICS 16..18(2015):2083-2097
